We are live on ! Find out more
AGMB

AgomAb Therapeutics NV
AGMB

32 hedge funds and large institutions have $245M invested in AgomAb Therapeutics NV in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

47.92% more ownership

Funds ownership: 0% → 47.92% (+48%)

Holders
32
Holders Change
+32
Holders Change %
–
% of All Funds
0.39%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.04%
New
32
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EFM
EQT Fund Management
Luxembourg
+$72.8M
2
S
Sanofi
France
+$39.4M
3
CAM
Cormorant Asset Management
Massachusetts
+$34.9M
4
TCM
TCG Crossover Management
California
+$29.1M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$22.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
EFM
1
EQT Fund Management
Luxembourg
$53.9M +$72.8M +5,141,992 New
S
2
Sanofi
France
$29.2M +$39.4M +2,783,096 New
CAM
3
Cormorant Asset Management
Massachusetts
$25.9M +$34.9M +2,465,348 New
TCM
4
TCG Crossover Management
California
$21.5M +$29.1M +2,053,233 New
Federated Hermes
5
Federated Hermes
Pennsylvania
$17M +$22.9M +1,618,000 New
CC
6
Casdin Capital
New York
$16.3M +$22M +1,550,000 New
AP
7
Andera Partners
$16.1M +$21.8M +1,538,702 New
Fidelity Investments
8
Fidelity Investments
Massachusetts
$15.3M +$20.7M +1,458,677 New
NCM
9
Nantahala Capital Management
Connecticut
$12.9M +$17M +1,200,000 New
Aberdeen Group
10
Aberdeen Group
United Kingdom
$7.42M +$10M +707,656 New
PA
11
Perceptive Advisors
New York
$6.29M +$8.5M +600,000 New
SB
12
Samsara BioCapital
California
$6.29M +$8.5M +600,000 New
SL
13
Siren LLC
Connecticut
$4.31M +$5.82M +411,250 New
LP
14
LMR Partners
United Kingdom
$3.15M +$4.25M +300,000 New
SGM
15
Seven Grand Managers
New York
$2.1M +$2.83M +200,000 New
RG
16
Redmile Group
California
$1.64M +$2.21M +156,250 New
Millennium Management
17
Millennium Management
New York
$999K +$1.35M +95,233 New
P
18
Pfizer
New York
$814K +$1.06M +75,000 New
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$787K +$1.06M +75,000 New
BG
20
Bellevue Group
Switzerland
$525K +$708K +50,000 New
LCM
21
Laurion Capital Management
New York
$525K +$708K +50,000 New
SAM
22
Sectoral Asset Management
Quebec, Canada
$477K +$616K +43,500 New
Goldman Sachs
23
Goldman Sachs
New York
$375K +$506K +35,739 New
BGM
24
Burkehill Global Management
New York
$367K +$496K +35,000 New
Citadel Advisors
25
Citadel Advisors
Florida
$367K +$496K +35,000 New
1
2

AGMB Hedge Fund Activity: Q1 2026 in Review

32 of the 8,132 institutional investors tracked by Wall St. Rank reported a position in AgomAb Therapeutics NV (AGMB) for Q1 2026, worth a combined $245M.

Buyers outnumbered sellers: 32 funds opened new AGMB positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was EQT Fund Management, opening a new position worth an estimated $72.8M.

  • 32 institutional investors held AgomAb Therapeutics NV (AGMB) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $245M of AgomAb Therapeutics NV stock for Q1 2026.
  • 32 funds opened new AgomAb Therapeutics NV positions in Q1 2026 and 0 closed out, a net change of +32 holders.
  • The largest AgomAb Therapeutics NV buyer in Q1 2026 was EQT Fund Management, an estimated $72.8M added.

Based on aggregated 13F filings for Q1 2026.